216 related articles for article (PubMed ID: 22453235)
1. Detection of allosteric kinase inhibitors by displacement of active site probes.
Lebakken CS; Reichling LJ; Ellefson JM; Riddle SM
J Biomol Screen; 2012 Jul; 17(6):813-21. PubMed ID: 22453235
[TBL] [Abstract][Full Text] [Related]
2. Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase.
Johnson TK; Bochar DA; Vandecan NM; Furtado J; Agius MP; Phadke S; Soellner MB
Angew Chem Int Ed Engl; 2021 Sep; 60(37):20196-20199. PubMed ID: 34292655
[TBL] [Abstract][Full Text] [Related]
3. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
5. A fluorescence lifetime based binding assay to characterize kinase inhibitors.
Lebakken CS; Hee Chol Kang ; Vogel KW
J Biomol Screen; 2007 Sep; 12(6):828-41. PubMed ID: 17644772
[TBL] [Abstract][Full Text] [Related]
6. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
Hantschel O; Grebien F; Superti-Furga G
Cancer Res; 2012 Oct; 72(19):4890-5. PubMed ID: 23002203
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.
Dong J; Lu W; Pan X; Su P; Shi Y; Wang J; Zhang J
Bioorg Med Chem; 2014 Dec; 22(24):6876-84. PubMed ID: 25464886
[TBL] [Abstract][Full Text] [Related]
8. Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II).
Schröter T; Minond D; Weiser A; Dao C; Habel J; Spicer T; Chase P; Baillargeon P; Scampavia L; Schürer S; Chung C; Mader C; Southern M; Tsinoremas N; LoGrasso P; Hodder P
J Biomol Screen; 2008 Jan; 13(1):17-28. PubMed ID: 18227223
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors.
Register AC; Chakraborty S; Maly DJ
Methods Mol Biol; 2017; 1636():79-89. PubMed ID: 28730474
[TBL] [Abstract][Full Text] [Related]
10. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
12. Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Adrián FJ; Ding Q; Sim T; Velentza A; Sloan C; Liu Y; Zhang G; Hur W; Ding S; Manley P; Mestan J; Fabbro D; Gray NS
Nat Chem Biol; 2006 Feb; 2(2):95-102. PubMed ID: 16415863
[TBL] [Abstract][Full Text] [Related]
13. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
Fasano M; Della Corte CM; Califano R; Capuano A; Troiani T; Martinelli E; Ciardiello F; Morgillo F
Expert Opin Investig Drugs; 2014 Jun; 23(6):809-21. PubMed ID: 24673358
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
15. Allosteric lariat peptide inhibitors of Abl kinase.
Bharathikumar VM; Barreto K; Decoteau JF; Geyer CR
Chembiochem; 2013 Nov; 14(16):2119-25. PubMed ID: 24030821
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site.
Chen H; Tucker J; Wang X; Gavine PR; Phillips C; Augustin MA; Schreiner P; Steinbacher S; Preston M; Ogg D
Acta Crystallogr D Struct Biol; 2016 May; 72(Pt 5):682-93. PubMed ID: 27139631
[TBL] [Abstract][Full Text] [Related]
17. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity.
Lemeer S; Zörgiebel C; Ruprecht B; Kohl K; Kuster B
J Proteome Res; 2013 Apr; 12(4):1723-31. PubMed ID: 23495751
[TBL] [Abstract][Full Text] [Related]
18. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform.
Lebakken CS; Riddle SM; Singh U; Frazee WJ; Eliason HC; Gao Y; Reichling LJ; Marks BD; Vogel KW
J Biomol Screen; 2009 Sep; 14(8):924-35. PubMed ID: 19564447
[TBL] [Abstract][Full Text] [Related]
19. Allosteric small-molecule kinase inhibitors.
Wu P; Clausen MH; Nielsen TE
Pharmacol Ther; 2015 Dec; 156():59-68. PubMed ID: 26478442
[TBL] [Abstract][Full Text] [Related]
20. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
